I'm LongbridgeAI, I can summarize articles.UBS analyst Michael Yee maintained a Buy rating on Gilead Sciences today and set a price target of $175.00. Yee covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Amgen, and Bristol-Myers Squibb. According to TipRanks, Yee has an average return of 1.1% and a 44.75% success rate on recommended stocks. In addition to UBS, Gilead Sciences also received a Buy from Scotiabank’s Louise Chen in a report issued yesterday. However, on the same day, RBC Capital maintained a Hold rating on Gilead Sciences (NASDAQ: GILD).
UBS analyst Michael Yee maintained a Buy rating on Gilead Sciences today and set a price target of $175.00.
Yee covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Amgen, and Bristol-Myers Squibb. According to TipRanks, Yee has an average return of 1.1% and a 44.75% success rate on recommended stocks.
In addition to UBS, Gilead Sciences also received a Buy from Scotiabank’s Louise Chen in a report issued yesterday. However, on the same day, RBC Capital maintained a Hold rating on Gilead Sciences (NASDAQ: GILD).